Halcox, Julian

ESC/EAS Guidelines for the management of dyslipidaemias

Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3,549

Circulating endothelial progenitor cells, vascular function, and cardiovascular risk

Hill, J. M., Zalos, G., Halcox, J. P. J., Schenke, W. H., Waclawiw, M. A., Quyyumi, A. A., & Finkel, T. (2003) · New England Journal of Medicine

Cardiovascular Health and Disease PreventionAngiogenesis and VEGF in Cancer

Cited by 3,423

Endothelial Function and Dysfunction: Testing and Clinical Relevance

Deanfield, J. E., Halcox, J. P., & Rabelink, T. J. (2007) · Circulation

Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease Prevention

Cited by 2,710

Prognostic Value of Coronary Vascular Endothelial Dysfunction

Halcox, J. P. J., Schenke, W. H., Zalos, G., Mincemoyer, R., Prasad, A., Waclawiw, M. A., Nour, K. R. A., & Quyyumi, A. A. (2002) · Circulation

Cardiovascular Health and Disease PreventionCardiac Imaging and Diagnostics

Cited by 1,385

ESC/EAS Guidelines for the management of dyslipidaemias

Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 706

Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study

Halcox, J. P. J., Wareham, K., Cardew, A., Gilmore, M., Barry, J. P., Phillips, C., & Gravenor, M. B. (2017) · Circulation

Atrial Fibrillation Management and OutcomesECG Monitoring and Analysis

Cited by 580

Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls

Bannister, C. A., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., & Currie, C. J. (2014) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementMetabolism, Diabetes, and Cancer

Cited by 356

Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study

Banegas, J. R., Lopez-Garcia, E., Dallongeville, J., Guallar, E., Halcox, J. P., Borghi, C., Masso-Gonzalez, E. L., Jimenez, F. J., Perk, J., Steg, P. G., et al. (2011) · European Heart Journal

Health Promotion and Cardiovascular PreventionCardiovascular Health and Risk Factors

Cited by 354

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials

Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism

Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic Diseases

Cited by 194

ESC/EAS Guidelines for the management of dyslipidaemias

Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 192

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., Jukema, J. W., Landmesser, U., López-Jaramillo, P., Manvelian, G., Pordy, R., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 150

A comparison of echocardiography and magnetic resonance imaging in cardiovascular screening of adults with Turner syndrome

Ostberg, J. E., Brookes, J. A. S., McCarthy, C., Halcox, J., & Conway, G. S. (2004) · The Journal of Clinical Endocrinology & Metabolism

Aortic Disease and Treatment ApproachesConnective tissue disorders research

Cited by 146

Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study

Halcox, J. P., Banegas, J. R., Roy, C., Dallongeville, J., De Backer, G., Guallar, E., Perk, J., Hajage, D., Henriksson, K. M., & Borghi, C. (2017) · BMC Cardiovascular Disorders

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 122

Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study

Borghi, C., Tubach, F., De Backer, G., Dallongeville, J., Guallar, E., Medina, J., Perk, J., Roy, C., Banegas, J. R., Rodriguez-Artalejo, F., et al. (2016) · International Journal of Cardiology

Blood Pressure and Hypertension StudiesClinical practice guidelines implementation

Cited by 102

Low-dose sodium nitrite attenuates myocardial ischemia and vascular ischemia-reperfusion injury in human models

Ingram, T. E., Fraser, A. G., Bleasdale, R. A., Ellins, E. A., Margulescu, A. D., Halcox, J. P., & James, P. E. (2013) · Journal of the American College of Cardiology

Cardiac Ischemia and ReperfusionNitric Oxide and Endothelin Effects

Cited by 69